Descovy®(emtricitabine/tenofovir alafenamide) – Expanded indication, new strength
On January 7, 2022, the FDA approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide), in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg and less than 35 kg.
Top